The 1st Issue published on February 28, 2021.   A Cell Press partner journal
On the cover: White background and black font are used to commemorate the death of COVID-19 patients in this SARS-CoV-2 pandemic. We hope that, under the guide of earth sustainable development and deep space exploration, the whole world will become better and better through the humanity efforts together.
Related comments£ŗ
 
Add comment (English only)
Name*:
E-mail:
Telephone:
Code:  
Comments*:
 Position: Home > issue > The 3rd Issue (November 25, 2020)
Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021
Category: Translational Patent
Author: Chan Li, Jing Xu, Yaling Gan, Xing-Jie Liang

gr1.jpg

TEM Image and Key Preclinical Results of IH-NM


Recent progress at the National Center for Nanoscience and Technology of China has enabled an extremely facile method to encapsulate irinotecan (CPT-11) into micelle-based nanoparticles (named as IH-NM). In preclinical study, compared with free CPT-11, IH-NM exhibited 1.56-fold higher maximum tolerance dose (MTD), ”«2.70-fold higher antitumor efficacy at 80% of MTD dosage, higher plasma exposure, and slower clearance from the plasma. The IH-NM technology received Clinical Trial Permission from the National Medical Products Administration (NMPA) of China on Mar 6, 2019. The Phase I clinical trial is under preparation.


Cite this article

Li, C., Xu, J., Gan, Y. and Liang, X.-J. Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021. The Innovation 1 (3), 100057 (2020). doi: 10.1016/j.xinn.2020.100057





[Printing]  [Close] 
Host:   Academic co-partner: Stay connected:
    SHANGHAI INSTITUTE OF APPLIED PHYSICS, CAS

  inquiry@the-innovation.org
  the.innovation.journal
  the.innovation.journal
  The_InnovationJ
  The Innovation““ŠĀ
  The Innovation““ŠĀ

Publishing partner:   INSTITUTE OF MICROBIOLOGY, CAS
  XI'AN INSTITUTE OF OPTICS AND PRECISION MECHANICS, CAS
  Copyright © 2019-2021 Youth Innovation All Rights Reserved